Literature DB >> 20226194

Design of an optimized scaffold for affibody molecules.

Joachim Feldwisch1, Vladimir Tolmachev, Christofer Lendel, Nina Herne, Anna Sjöberg, Barbro Larsson, Daniel Rosik, Eva Lindqvist, Gunilla Fant, Ingmarie Höidén-Guthenberg, Joakim Galli, Per Jonasson, Lars Abrahmsén.   

Abstract

Affibody molecules are non-immunoglobulin-derived affinity proteins based on a three-helical bundle protein domain. Here, we describe the design process of an optimized Affibody molecule scaffold with improved properties and a surface distinctly different from that of the parental scaffold. The improvement was achieved by applying an iterative process of amino acid substitutions in the context of the human epidermal growth factor receptor 2 (HER2)-specific Affibody molecule Z(HER2:342). Replacements in the N-terminal region, loop 1, helix 2 and helix 3 were guided by extensive structural modeling using the available structures of the parent Z domain and Affibody molecules. The effect of several single substitutions was analyzed followed by combination of up to 11 different substitutions. The two amino acid substitutions N23T and S33K accounted for the most dramatic improvements, including increased thermal stability with elevated melting temperatures of up to +12 degrees C. The optimized scaffold contains 11 amino acid substitutions in the nonbinding surface and is characterized by improved thermal and chemical stability, as well as increased hydrophilicity, and enables generation of identical Affibody molecules both by chemical peptide synthesis and by recombinant bacterial expression. A HER2-specific Affibody tracer, [MMA-DOTA-Cys61]-Z(HER2:2891)-Cys (ABY-025), was produced by conjugating MMA-DOTA (maleimide-monoamide-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to the peptide produced either chemically or in Escherichia coli. ABY-025 showed high affinity and specificity for HER2 (equilibrium dissociation constant, K(D), of 76 pM) and detected HER2 in tissue sections of SKOV-3 xenograft and human breast tumors. The HER2-binding capacity was fully retained after three cycles of heating to 90 degrees C followed by cooling to room temperature. Furthermore, the binding surfaces of five Affibody molecules targeting other proteins (tumor necrosis factor alpha, insulin, Taq polymerase, epidermal growth factor receptor or platelet-derived growth factor receptor beta) were grafted onto the optimized scaffold, resulting in molecules with improved thermal stability and a more hydrophilic nonbinding surface. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226194     DOI: 10.1016/j.jmb.2010.03.002

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  46 in total

1.  Synthetic and natural consensus design for engineering charge within an affibody targeting epidermal growth factor receptor.

Authors:  Brett A Case; Benjamin J Hackel
Journal:  Biotechnol Bioeng       Date:  2016-02-04       Impact factor: 4.530

Review 2.  NextGen protein design.

Authors:  Nicholas Sawyer; Elizabeth B Speltz; Lynne Regan
Journal:  Biochem Soc Trans       Date:  2013-10       Impact factor: 5.407

3.  68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.

Authors:  Gabriela Kramer-Marek; Nalini Shenoy; Jurgen Seidel; Gary L Griffiths; Peter Choyke; Jacek Capala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

4.  A Gradient of Sitewise Diversity Promotes Evolutionary Fitness for Binder Discovery in a Three-Helix Bundle Protein Scaffold.

Authors:  Daniel R Woldring; Patrick V Holec; Lawrence A Stern; Yang Du; Benjamin J Hackel
Journal:  Biochemistry       Date:  2017-03-09       Impact factor: 3.162

5.  ScaffoldSeq: Software for characterization of directed evolution populations.

Authors:  Daniel R Woldring; Patrick V Holec; Benjamin J Hackel
Journal:  Proteins       Date:  2016-04-16

6.  Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines.

Authors:  Jennie Malmberg; Vladimir Tolmachev; Anna Orlova
Journal:  Exp Ther Med       Date:  2011-02-22       Impact factor: 2.447

Review 7.  Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.

Authors:  Jacek Capala; Kirsten Bouchelouche
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

8.  Advancing Molecular-Guided Surgery through probe development and testing in a moderate cost evaluation pipeline.

Authors:  Brian W Pogue; Keith D Paulsen; Sally M Hull; Kimberly S Samkoe; Jason Gunn; Jack Hoopes; David W Roberts; Theresa V Strong; Daniel Draney; Joachim Feldwisch
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2015-03-04

9.  Molecular imaging of insulin-like growth factor 1 receptor in cancer.

Authors:  Yin Zhang; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

10.  Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Authors:  Irina Velikyan; Anders Wennborg; Joachim Feldwisch; Henrik Lindman; Jörgen Carlsson; Jens Sörensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.